Chelsie Ferrell, PA
Medical · Deland, FLNPI 1609204494
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $93,115 of the $132,096 with a category attached, or 70.5%. Johnson & Johnson accounts for 92.5% of it on its own, with 36 other manufacturers making up the rest. Reporting peaked in 2023 at $34,903 and has fallen 53.6% since, to $16,184 in 2025. Among medical clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 401 payments — averaging $329.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$122K
- Pfizer$3K
- Bayer$2K
- Janssen Scientific Affairs, LLC$899
- Astellas Pharma US Inc$855
- Procept Biorobotics Corporation$531
- plus $3K from 31 others
What the payments were for
- Consulting fees$7,8536%
- Speaking & faculty fees$93,11570%
- Travel & lodging$20,98616%
- Food & beverage$9,8157%
- Education$3270%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 238 | $122,187 |
| Pfizer | 11 | $2,612 |
| Bayer | 15 | $1,883 |
| Janssen Scientific Affairs, LLC | 4 | $899 |
| Astellas Pharma US Inc | 29 | $855 |
| Procept Biorobotics Corporation | 4 | $531 |
| Myriad Genetic Laboratories, Inc. | 15 | $279 |
| Bioprotect Medical, Inc. | 3 | $272 |
| Merck | 8 | $264 |
| Teleflex LLC | 4 | $223 |
| AstraZeneca | 9 | $177 |
| Dendreon Pharmaceuticals LLC | 7 | $168 |
| Tempus AI, Inc | 4 | $147 |
| Progenics Pharmaceuticals, Inc. | 4 | $141 |
| Coloplast | 4 | $134 |
| Tolmar Pharmaceuticals, Inc. | 2 | $130 |
| Ferring Pharmaceuticals Inc. | 2 | $128 |
| Boston Scientific | 2 | $120 |
| Medtronic | 1 | $118 |
| AbbVie | 6 | $108 |
| Telix Pharmaceuticals | 1 | $103 |
| Endo Pharmaceuticals Inc. | 4 | $88 |
| Seagen Inc. | 1 | $85 |
| Myovant Sciences Inc. | 4 | $76 |
| Foundation Medicine, Inc. | 2 | $65 |
| Sun Pharmaceutical Industries Inc. | 3 | $52 |
| Calyxo, Inc. | 2 | $38 |
| Accord Healthcare, Inc. | 2 | $35 |
| Antares Pharma, Inc. | 2 | $31 |
| Sumitomo Pharma America, Inc. | 1 | $23 |
| Dentsply IH Inc. | 1 | $20 |
| Verity Pharmaceuticals Inc. | 1 | $20 |
| Blue Earth Diagnostics | 1 | $20 |
| Amgen | 1 | $18 |
| Olympus America Inc. | 1 | $18 |
| Novartis | 1 | $16 |
| Laborie Medical Technologies Corp. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$132,096 in reported general payments places this provider in the 95th percentile of 2,031 medical providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 26 | $28,920 |
| GemtesaVibegron | 23 | $22,952 |
| Tamsulosin Hcl | 229 | $3,462 |
| Solifenacin Succinate | 76 | $2,597 |
| Potassium Citrate ErPotassium Citrate | 15 | $1,234 |
| Finasteride | 115 | $1,223 |
| Estradiol | 21 | $1,198 |
| Doxycycline Hyclate | 133 | $924 |
| NitrofurantoinNitrofurantoin Macrocrystal | 14 | $343 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 16 | $311 |
| Oxybutynin Chloride ErOxybutynin Chloride | 13 | $191 |
| Tramadol Hcl | 52 | $154 |
| Ciprofloxacin Hcl | 17 | $66 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 18 | $56 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $855 | $28,92026 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $23 | $22,95223 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,031 medical providers in Florida.
Other medical in Deland
- Gary RubinRockledge$2.1M
- Shanna MirantiNaples$415K
- Krystie LennoxBoca Raton$245K
- Jihan RamadanWellington$238K
- Ilanit SamuelsMiami$211K
- Erin DouceyWinter Haven$202K
- Kathleen TrummerWellington$166K
- Sandra SnyderTampa$156K
- Francine PhillipsLand O Lakes$145K
- Jessica PackwoodOrlando$129K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.